Praxis Precision Medicines (PRAX) Stock
Biotech company developing precision treatments for brain disorders. Here's the price, business snapshot, and what's worth knowing about Praxis Precision Medicines in June 2026.
Praxis Precision Medicines I (PRAX) is a clinical-stage biotechnology company focused on precision treatments for central nervous system (CNS) disorders. The business targets mechanism-driven therapies designed for specific patient subgroups, including genetically defined and functional neurological conditions. As a development-stage firm, its value is largely tied to research progress, clinical-trial milestones and regulatory decisions rather than steady revenues; current market capitalisation is about $4.69 billion. Investors should expect higher volatility common to biotechs: positive trial data can lift the share price, while setbacks or delays may reduce it. Due diligence should include review of trial phases, pipeline breadth, cash runway and partnership agreements. This summary is for educational purposes only and not investment advice — clinical and regulatory outcomes are uncertain, and past performance is not a guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PRAX's stock with a target price of $442.13, indicating significant growth potential.
Financial Health
PRAXIS is showing strong financial performance with healthy cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PRAX
Clinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: 31 July 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: 17 June 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: 17 June 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: 17 June 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline progress is led by trial milestones, which can create sharp share-price moves; this offers opportunity but also heightened risk.
Targeted science approach
Mechanism-driven therapies aim at specific patient groups, which can improve efficacy prospects yet depend on successful development and approvals.
News-driven volatility
Results, partner deals and funding news often drive market reactions; balance potential upside with the chance of setbacks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
